Related Experiment Videos
Cytotoxic T lymphocyte responses to Epstein-Barr virus
A B Rickinson1, S P Lee, N M Steven
1CRC Institute for Cancer Studies, Clinical Research Block, The Medical School, University of Birmingham, Edgbaston, B15 2TJ, UK. D.Williams.can@bham.ac.uk
Current Opinion in Immunology
|August 1, 1996
Summary
Epstein-Barr virus triggers a strong T cell response targeting specific latent antigens. These responses can control virus-linked growths, but broader targeting is needed for other tumors.
Area of Science:
- Immunology
- Virology
- Oncology
Background:
- Epstein-Barr virus (EBV) establishes lifelong infections.
- Cytotoxic T lymphocytes (CTLs) are crucial for controlling EBV-infected cells.
- EBV latent antigens are targets for immune surveillance.
Purpose of the Study:
- To investigate the immunodominance of EBV latent antigens.
- To understand the role of HLA class I processing in antigen presentation.
- To evaluate the therapeutic potential of T cell responses against EBV-associated diseases.
Main Methods:
- Analysis of T cell responses in EBV-infected individuals.
- Assessment of antigen processing and presentation pathways.
- Evaluation of effector cell function in vitro and in vivo models.
Main Results:
- A subset of EBV latent antigens elicits dominant CTL responses.
- Immunodominance correlates with preferential HLA class I pathway access.
- Therapeutic efficacy of CTLs against lymphoproliferative lesions was demonstrated.
Conclusions:
- EBV-specific CTLs targeting immunodominant antigens can control viral-induced growths.
- Subdominant latent antigens may require broader T cell responses for complete tumor eradication.
- Targeting specific EBV antigens offers potential for immunotherapy.